OBJECTIVES: Acquired von Willebrand syndrome, characterized by the reduction in von Willebrand factor (vWF) large multimers, has recently been considered as one of the causes of gastrointestinal bleeding (GIB). It remains unclear whether its haematological severity is linked with susceptibility to bleeding because the definition of the haematological severity of acquired von Willebrand syndrome has not been precisely determined. This study sought to establish a quantitative methodology to assess the haematological severity of acquired von Willebrand syndrome and to define the threshold for occurrence of GIB in patients implanted with left ventricular assist devices (LVADs).
INTRODUCTION
Left ventricular assist devices (LVADs) contribute to the treatment of end-stage heart failure [1, 2] . Bleeding complications, in particular gastrointestinal bleeding (GIB) [3] , occur in 10-33% of patients with continuous-flow types of LVADs [4, 5] . Recently, acquired von Willebrand syndrome (aVWS) induced by LVADs has been highlighted as a possible cause of GIB [6, 7] . von Willebrand factor (vWF) plays a critical role in haemostasis. It is cleaved into multimers composed of 2-80 subunits by ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin Type 1 motifs, member 13), an enzyme with specific vWF-cleaving activity in a shear stress-dependent manner [8] . High molecular weight multimers play important roles in haemostasis [9] . Unphysiologically high shear stress inside pumps induces excessive cleavage of vWF multimers, leading to a loss of such large multimers and a haemostatic disorder known as aVWS [10, 11] .
The degree of loss of vWF large multimers has been variably reported, since a quantitative methodology to define the loss of vWF large multimers has not been fully established. Therefore, it remains undetermined as to whether the severity of haematological aVWS is linked with LVAD-associated GIB [12] . To address this question, we quantitatively analysed vWF large multimers in 41 patients after an LVAD implantation, introducing the vWF large multimer index [13] and evaluated the association between the haematological severity of aVWS and the occurrence of GIB complications.
METHODS

Patients evaluated in this study
From July 2011 to June 2017, 47 patients underwent implantation of LVADs in Tohoku University Hospital. Six patients were excluded from the study, because they had undergone heart transplantation or passed away before the installation of vWF multimer analysis. Thus, 41 patients participated in the study. We performed vWF multimer analysis and followed patient clinical courses until June 2017. All 41 patients were treated with anticoagulant therapy with warfarin targeting prothrombin time-international normalized ratio (PT-INR) levels between 2.0 and 3.0, and also by antiplatelet therapy, principally with aspirin. Since 8 patients were aspirin intolerant, 7 of these were treated with an adenosine diphosphate receptor blocker clopidogrel, whereas 1 was treated with a phosphodiesterase 3-inhibitor cilostazol. At the early postoperative period, we titrated the dose of heparin targeting activated partial thromboplastin time (APTT) levels between 45 and 55 s until warfarin control was established. vWF large multimers were evaluated in our laboratory on Day 200 (median; range Day 3-1254) after an LVAD implantation under stable conditions rather than in the acute phase of bleeding. ADAMTS13 activity was measured at the same time, based on the FRETS-VWF73 assay [14] by SRL Co. (Tokyo, Japan). For the analysis, plasma was isolated in a platelet-free manner within 1 h after blood extraction and stored at -80 C until analysis.
Quantification of large multimers of von Willebrand factor
We first determined the concentrations of vWF in the plasma of the normal control subject and each patient by Western blot analysis under reduced conditions followed by densitometric analysis. The control plasma was prepared by extracting plasma from a single healthy person. A dispensed sample from the control plasma was consistently used for each time measurement throughout the entire study. The vWF antigen levels in the plasma of patient and control were determined by Western blot in a reduced condition. Then, plasma containing the same amount of vWF in each patient as that of the control was analysed in adjacent lanes by the vWF multimer analysis performed essentially as described [15] with polyclonal rabbit anti-human vWF antibody (DAKO, Glostrup, Denmark) as the primary antibody. The Western blots probing vWF were finally visualized by ImmunoStar V R Zeta chemiluminescence (Wako, Osaka, Japan) and evaluated by Image Quant LAS 4000 mini (GE Healthcare) and ImageJ as described previously [13] . Bands 1-5 (starting from the lowest molecular weight band) were classified as low, 6-10 as medium and all those >10 as large multimers. The vWF large multimer proportion was calculated as the densitometric area of those bands. The vWF large multimer index was defined as the ratio of the large multimer proportion in total vWF derived from a patient to that from a normal control analysed in the adjacent lane [13] . Using this index, the quantity of vWF large multimers in a patient was expressed as a percentage of its normal control value obtained with simultaneous analysis of each time measurement ( Fig. 1) .
Measurement of plasma von Willebrand factor antigen level and ristocetin cofactor activity vWF antigen (vWF: Ag) was measured by SRL Co. using the latex agglutination reaction with STA V R -LIATEST VWF: Ag (Roche Diagnostics, Switzerland). vWF ristocetin cofactor activity (vWF: RCo) was also analysed by SRL Co. with BC von Willebrand Reagent (Siemens, Germany).
Gastrointestinal bleeding events
GIB was defined as any clinically suspected or documented suspicion of bleeding from the gastrointestinal tract as indicated with a de novo fall in haemoglobin level and the appearance of melena, haematochezia, haematemesis or guaiac positive stools as described previously [4, 16] .
Statistical analyses
All statistical analyses were performed using JMP V R Pro version 13 (SAS Institute Inc., Cary, NC, USA). Continuous variables are expressed as mean ± standard deviation. Categorical variables are presented as frequency and percentages, and inter-group comparisons of categorical variables were analysed using Fisher's exact test or v 2 test. If a value in a cell was <5, the Fisher's exact test was applied. Intergroup comparison of continuous variables was performed using the Student's t-test or the Welch's t-test, if normally distributed; otherwise, Mann-Whitney U-test was used. Shapiro-Wilk test was applied to determine whether the variable follows a normal distribution. Kaplan-Meier methods were used to estimate GIB event-free survival. The median follow-up time was computed using the inverse Kaplan-Meier method. Receiver operating characteristic curves (ROC) were performed to identify the cut-off value of a vWF large multimer index. The difference was considered significant at a P-value <0.05.
Ethics
This study was performed in accordance with the Declaration of Helsinki. The study protocol was approved by the Institutional Ethics Committee in Tohoku University (Certification number; 2017-1-386). Written informed consent was obtained from each patient.
RESULTS
Patient characteristics
Patient demographics and clinical information categorized by the 2 different pump types are summarized in Table 1 . All patients were followed for a median of 591 days, and 28 patients were supported with LVADs throughout the follow-up periods. The remaining 13 patients were followed until the occurrence of the following events: heart transplantation in 5 patients on Days 591, 999, 1156, 1296 and 1550 after LVAD implantation; LVAD explantation in 1 patient due to severe device infection on Day 834; pump exchange in 4 patients on Days 384, 681, 778 and 434; and death in 3 patients on Days 248, 892 and 1361, respectively. No significant differences were observed in age, sex or aetiology between patients treated with axial (n = 33) and centrifugal (n = 8) types of LVADs (Table 1) .
Gastrointestinal bleeding complications
While thrombotic events of cerebral infarction, superior mesenteric artery thrombosis and pump thrombosis occurred in 7 patients and severe device infection occurred in 3 patients during the follow-up periods, GIB complications occurred in 12 (29%) patients at the median LVAD support time of 179 days (range 14-1106 days) ( Tables 1 and 2 ). Ten GIB patients were supported with axial-type LVADs, and the other 2 with centrifugal-type LVADs. Mean haemoglobin levels in the acute bleeding phase of the 12 patients were 77.9 ± 17.1 g/l, suggesting that relatively large amounts of blood were lost on the bleeding events, whereas their PT-INR and APTT were within therapeutic ranges. The GIB-free survival curve indicated a 6-month event-free survival of 85.3%, 1-year survival of 77.0% and 2-year survival of 73.0% by the KaplanMeier method (Fig. 2) . Four patients (Cases 1-4, Table 2 ) developed GIB in the early periods of 14-40 days after LVAD implantation. In 2 of these patients, bleeding lesions were detected by endoscopy. The bleeding sites contained oozing haemorrhages from ulcers and/or erosions, and angiodysplasia was not detected in either patient. On the other hand, GIB events occurred in the remaining 8 patients (Cases 5-12, Table 2 ) in the later periods of Day 142 and after. Upper and/or lower gastrointestinal examinations did not identify distinct bleeding lesions except for 2 patients. The origin of both bleeds in Case 5 at Day 142 and in Case 9 at Day 266 was confirmed to be angiodysplasia.
The characteristics of the LVAD patients with or without GIB are summarized in Table 3 . No significant differences were observed in gender, age, aetiology of heart disease, pump types or haematological data between the 2 groups using the Fisher's exact test. All 
Evaluation of vWF large multimers by the vWF large multimer index
All LVAD patients exhibited severe loss of vWF large multimers [18] , with a mean index of 33.8 ± 16.8%. With regard to pump types, vWF large multimer indices in patients with axial-type LVADs were significantly lower compared to those with centrifugal-type LVADs (31.4 ± 16.7% vs 43.8 ± 14.2%, P = 0.030) by the Student's t-test (Fig. 3) . Those in patients with GIB were significantly lower compared to those without GIB (25.0 ± 10.3% vs 37.5 ± 17.8%, P = 0.008) by the Welch's t-test (Fig. 4) . Notably, all the patients with GIB exhibited indices below 40%, and no patients with an index above 40% developed GIB. Furthermore, 12 (41%) of the 29 patients with indices below 40% experienced GIB during the median follow-up period of 591 days. ROC identified the cut-off value for vWF large multimer on GIB as 39.4% (sensitivity 100%, specificity 41.4%) (see Supplementary Material, Fig. S1 ). On the other hand, the other parameters including vWF: Ag (103.6 ± 50.4% vs 116.4 ± 57.7%, P = 0.74), vWF: RCo (49.8 ± 39.0% vs 61.3 ± 44.2%, P = 0.78), vWF: RCo/vWF: Ag (0.52 ± 0.28 vs 0.42 ± 0.22, P = 0.85) and ADAMTS13 activities (120.6 ± 35.3% vs 125.5 ± 36.6%, P = 0.69) were not statistically different (GIB group vs Non-GIB group, respectively) by the Student's t-test or the Welch's t-test, when appropriate.
DISCUSSION
In this study, we have quantitatively evaluated the loss of vWF large multimers that could indicate the haematological severity of aVWS in 41 patients after an LVAD implantation. We have demonstrated that GIB occurred in 12 (29%) patients who exhibited a more severe loss of vWF large multimers than those without GIB. Further, cut-off value for vWF large multimer index on GIB was 39.4% by ROC analysis. Thus, aVWS in a severe form associated with a certain threshold of multimer index may dictate the risk of LVAD-associated GIB during the course of follow-up. vWF multimer analysis and measurement of activity of ADAMTS13 were performed with patients in the stable state.
c Case 3 was presented previously [17] . ADAMTS13: a disintegrin and metalloproteinase with thrombospondin type 1 motifs, member 13; DCM: dilated cardiomyopathy; dHCM: dilated phase of hypertrophic cardiomyopathy; GIB: gastrointestinal bleeding;
Hb: haemoglobin; ICM: ischaemic cardiomyopathy; PT-INR: prothrombin time-international normalized ratio; rpm: revolutions per minute; vWF: von Willebrand factor; vWF: RCo/vWF: Ag: ristocetin cofactor activity: von Willebrand factor antigen ratio.
In some previous studies, vWF large multimers were evaluated by vWF large multimer ratios [13, 19, 20] . In a study by Tamura et al. [13] analysing 31 severe aortic stenosis patients, vWF large multimer ratios were decreased in a pressure gradient-dependent manner. Their study demonstrated that the ratios were distributed predominantly between 10% and 35%, although these ratios overlapped extensively with those of normal controls analysed simultaneously [13] . In another study, vWF large multimer ratios have also been shown to decrease depending on the severity of aortic stenosis where by ratios were distributed between 4% and 14% [19] . Furthermore, Meyer et al. [20] demonstrated that in 102 patients treated with LVAD, pump speed was weakly, but significantly, correlated inversely with vWF large multimer ratios distributed between 20% and 60%. It has been reported that vWF multimer profiles do not correlate with the incidence of bleeding complications [20] . Thus, although these ratios may indicate some association with clinical parameters, the absolute values of the vWF large multimer ratios vary considerably between studies. Therefore, it would be difficult to use the ratios for comparison across studies. ROC vWF large multimer analysis is categorized as a manoeuvre of Western blotting [15] , the results obtained would appear to be influenced by the vWF antigen amount to be analysed and the exposure time in the final visualization procedure. Variability of vWF large multimer ratios may be attributable to those factors associated with laboratory work. To avoid such variability, we have recently proposed a novel value, namely the vWF large multimer index [13] , since the index is a relative value using vWF large multimers of a normal control as a reference.
We further confirmed using our quantitative method that the axial pump group exhibited more severe loss of vWF large multimers than the centrifugal pump group as shown previously [20, 21] . It is notable that 39.4% could be a predictive value for subsequent GIB in patients treated with continuous-flow-type LVADs, irrespective of either axial-or centrifugal-type pump involvement.
This index may also be useful in avoiding GIB complications by titrating the intensity of antithrombotic therapy, since vWF is a platelet-binding factor and plays a critical role in haemostasis. It may be worthwhile to consider modifying an the antithrombotic regimen for patients developing severe aVWS, who exhibit a vWF large multimer index lower than 40%. However, since the number of patients in this study was small, a modification of the anticoagulation and antiplatelet therapy protocol in patients with LVAD-associated aVWS warrants further larger scale clinical investigation to establish conclusive evidence.
The causes of GIB are clinically considered to be multifactorial. Having severe aVWS as a substrate, development of gastrointestinal ulcer at an early stage and angiodysplasia at a later stage may evoke GIB as a superimposed factor in patients treated with LVAD. In our present study, the majority of GIB patients did not have a clear cause of GIB, and only 4 patients were clearly found to have bleeding lesions such as ulcer, erosion and angiodysplasia. Among those 4 patients the mean value of the vWF multimer index was 25.2%, whereas the patients without clear causes of GIB exhibited a mean index of 28.8%. There were no significant differences (P = 0.67) in those values. The correlation between the vWF large multimer index and development of gastrointestinal organic lesion was not prove, so further study will be required to clarify this issue.
Limitations
The limitations to this study include the fact that it was a retrospective single-centre study with a small number of patients. Further study is required for unequivocal establishment of the vWF large multimer index as a predictive measure for GIB complications in patients implanted with LVADs.
CONCLUSIONS
The vWF large multimer index, which is a novel quantitative methodology employed to evaluate the haematological severity of aVWS, was applied in all 41 patients after LVAD implantation. Using this index, patients with GIB exhibited more severe aVWS compared to those without GIB haematologically. GIB patients exhibited severe aVWS with large multimer indices of approximately < _40%. The vWF large multimer index may predict a risk of GIB after an LVAD implantation.
